Theravance Inc., of South San Francisco, and Glaxosmithkline plc, of London, said the European Committee for Medicinal Products for Human Use issued a positive opinion recommending marketing authorization for umeclidinium/vilanterol (UMEC/VI), under the proposed brand name Anoro, as a once-daily maintenance bronchodilator to relieve symptoms in adults with chronic obstructive pulmonary disease.